Access cutting-edge macular degeneration treatment through this clinical trial at a research site in Campbell. Study-provided care at no cost to qualified participants.
Access macular degeneration specialists in Campbell at no cost
This study follows strict safety protocols and ethical guidelines
All study-related macular degeneration treatment provided free
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies ha
Sponsor: AbbVie
Check if you qualify for this macular degeneration clinical trial in Campbell, CA
If you're searching for macular degeneration treatment options in Campbell, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Campbell research site is actively enrolling participants for this clinical trial. You'll receive care from experienced macular degeneration specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.